Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
) to Absorb Subsidiary
5/23/2007 11:08:08 AM
BRUSSELS (Thomson Financial) - Belgian biotechnology company ThromboGenics NV said it plans to absorb its subsidiary Thromb-X. The company said the transaction will issue no new shares or cash payment.
(THR.BR) Announces Progress With its Pre-Clinical and Clinical Programs
(HOLX) to Buy
) for About $6.2 Billion
(THR.BR) Successfully Completes Private Share Offering Raising EUR23.9 Million
Sun Pharmaceutical Industries Ltd
Taro Pharmaceutical Industries Ltd.
(TARO) for $454 Million, Shares Up
(THR.BR) Signs Licensing Deal with
Warburg, Pincus Ventures, L.P.
Bausch & Lomb
(BOL); Transaction Valued at $4.5 Billion
Becomes Major Shareholder in
Bio-Rad Laboratories, Inc.
(BIO) Says to Acquire
Diamyd Medical AB
for $392.6 Million
Enter Into Agreement For Exclusive Sale And Marketing Of New Embryonic Stem Cell Tissue Culture Media
Mylan Laboratories Inc.
(MYL) to Acquire Generics Business of
(MKGAF.PK) for $6.6 Billion
comments powered by Disqus.
comments powered by
Biotech/Pharma - Mergers and Acquisitions